ATLANTA — The investigational ultra long-acting injectable GLP-1 receptor agonist (RA) MET-097 produced up to 14% weight loss, with the potential for improved tolerability compared with other GLP-1 ...
Phase 1 trial shows MBX 1416 is safe and well-tolerated, advancing to Phase 2 for PBH in late 2025. MBX Biosciences announced positive Phase 1 clinical trial results for its investigational drug MBX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results